Literature DB >> 12488983

Embryonal hyperplasia of Bowman's capsular epithelium in patients with WT1 mutations.

Ryuji Fukuzawa1, Michael R Eccles, Masahiro Ikeda, Jun-ichi Hata.   

Abstract

Embryonal hyperplasia of Bowman's capsular epithelium (EHBCE) is a rare condition, observed in patients with end-stage renal disease when treated with long-term dialysis. Immunohistochemical studies have suggested that EHBCE originates from the visceral epithelium of the Bowman's capsule. Here we report two patients with WT1 missense mutations in exon 7, who received continuous ambulatory peritoneal dialysis and developed EHBCE without Wilms tumor. One patient showed manifestations of Denys-Drash syndrome (DDS), while the other patient exhibited rapid progress into end-stage renal disease, but no genitourinary anomaly. Recently, abnormal expression of WT1 and PAX2 was shown in the podocytes in diffuse mesangial sclerosis (DMS) associated with DDS and isolated DMS. We hypothesize that EHBCE is a reversion of Bowman's capsular epithelial cells to an earlier cell differentiation state, which has the characteristics of a progenitor cell of both Bowman's capsular epithelia and podocytes. Immunohistochemical analysis of WT1, PAX2, vimentin, cytokeratin, and epithelial membrane antigen was performed in the kidney specimens obtained at autopsy or surgery. Abnormal expression of WT1 and PAX2 in the EHBCE was observed in both patients, supporting our hypothesis. The nephropathy associated with constitutional WT1 mutations might therefore be associated with EHBCE.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12488983     DOI: 10.1007/s00467-002-1019-7

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  1 in total

1.  PAX2 is dispensable for in vitro nephron formation from human induced pluripotent stem cells.

Authors:  Yusuke Kaku; Atsuhiro Taguchi; Shunsuke Tanigawa; Fahim Haque; Tetsushi Sakuma; Takashi Yamamoto; Ryuichi Nishinakamura
Journal:  Sci Rep       Date:  2017-07-03       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.